Are preoperative inflammatory and nutritional markers important for the prognosis of patients with peritoneal metastasis of colorectal cancer?

Table 1 Summary of the results found in the original article

Parameter	n among 133 patients	Most common age in years	Most common sex	Normal albumin, ≥ 35 g/L	Tumor most prevalent location	Most common histology	Number of patients with CC 0/11	Number of patients treated with HIPEC2
High NLR	54 (40.6)	≥ 60 (54.1)	Men	46 (85.1)	Left side of the colon	Adenocarcinoma	30 (55.6)	16 (29.6)
Low NLR	79 (59.4)			53 (67.1)			27 (34.1)	19 (24.1)
Normal Hb	94 (70.7)	< 60 (58.5)		78 (82.9)			49 (52.1)	29 (30.8)
Low Hb	39 (29.3)	≥ 60 (64.1)		21 (53.9)			8 (20.5)	6 (15.3)

Data are n (%).

¹Patients with cytoreduction scores of 0 or 1 were considered eligible for hyperthermal intraperitoneal chemotherapy.

²Among the patients pre-selected for hyperthermal intraperitoneal chemotherapy, only those deemed capable of tolerating the procedure received the treatment.

CC: Cytoreduction; Hb: Hemoglobin; HIPEC: Hyperthermal intraperitoneal chemotherapy; NLR: Neutrophil-to-lymphocyte ratio.

Table 2 Clinical relevance of the association between neutrophil-to-lymphocyte ratio, hemoglobin, and colorectal cancer prognosis

Parameter	High NLR	Low Hb
Clinical associated factors	Higher secretion of chemokines and inflammatory cytokines	Anemia and iron losses (bleeding, ingestion and absorption deficiency)
Clinical outcomes	Suppression of apoptosis, increased proliferation, migration, and invasion of tumor cells, and organ dysfunction	Reduced erythropoiesis, low iron release, cachexia
Number of patients admitted with CRC-PM (poor prognosis)	40.6% (54/133)	70.6% (94/133)

CRC: Colorectal cancer; Hb: Hemoglobin; NLR: Neutrophil-to-lymphocyte ratio.